What is Denali Therapeutics Inc.'s cumulative cost basis?

Denali Therapeutics Inc. (DNLI) reported cumulative cost basis of $664.17M in Q1 2026.

How has Denali Therapeutics Inc.'s cumulative cost basis changed year-over-year?

Denali Therapeutics Inc.'s cumulative cost basis decreased by 33.2% year-over-year, from $994.43M to $664.17M.

What is the long-term trend for Denali Therapeutics Inc.'s cumulative cost basis?

Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cumulative cost basis has grown at a -5.3% compound annual growth rate (CAGR), from $995.15M to $759.84M.

Denali Therapeutics Inc. DNLI Cumulative Cost Basis

Cumulative Cost Basis at other companies

Regeneron PharmaceuticalsREGN

——

BiogenBIIB

——

BridgeBio PharmaBBIO

——

Krystal Biotech, Inc.KRYS

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s cumulative cost basis?: Denali Therapeutics Inc. (DNLI) reported cumulative cost basis of $664.17M in Q1 2026.
How has Denali Therapeutics Inc.'s cumulative cost basis changed year-over-year?: Denali Therapeutics Inc.'s cumulative cost basis decreased by 33.2% year-over-year, from $994.43M to $664.17M.
What is the long-term trend for Denali Therapeutics Inc.'s cumulative cost basis?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cumulative cost basis has grown at a -5.3% compound annual growth rate (CAGR), from $995.15M to $759.84M.